.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX03_Pazopanib.Pazopanib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX03_Pazopanib.Pazopanib| name: | Pazopanib |
| ATC code: | L01EX03 | route: | oral |
| n-compartments | 2 |
Pazopanib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-Kit. It is primarily used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. Pazopanib is approved by regulatory agencies and is currently in clinical use for these indications.
Pharmacokinetic parameters in adult patients with advanced solid tumors; healthy male and female, multiple ethnicities, after oral administration of pazopanib tablets.
Imbs, DC, et al., & Chatelut, E (2014). Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer chemotherapy and pharmacology 73(6) 1189–1196. DOI:10.1007/s00280-014-2455-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24705975
Turner, DC, et al., & Stewart, CF (2013). Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer. Anticancer research 33(9) 3823–3829. PUBMED:https://pubmed.ncbi.nlm.nih.gov/24023315
McLaughlin, MM, et al., & Kim, RY (2013). Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration. JAMA ophthalmology 131(12) 1595–1601. DOI:10.1001/jamaophthalmol.2013.5002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24113783